https://preview.ask-biosimilars.com/resources/cancer-centre-develops-standardised-approach-to-evaluate-and-implement-biosimilars/ 2021-10-05T08:43:47+00:00 https://preview.ask-biosimilars.com/resources/how-best-to-illustrate-interchangeability-of-biosimilars-abstract/ 2021-10-05T08:45:05+00:00 https://preview.ask-biosimilars.com/resources/comparison-of-aspects-of-available-lmwh-biosimilars-abstract/ 2021-10-05T08:45:33+00:00 https://preview.ask-biosimilars.com/resources/understanding-of-biosimilars-among-hcps-key-to-driving-uptake-abstract/ 2021-10-05T08:45:38+00:00 https://preview.ask-biosimilars.com/resources/trastuzumab-biosimilar-and-cardiac-toxicity-lilac-study-abstract/ 2021-10-05T08:45:53+00:00 https://preview.ask-biosimilars.com/ressourcen/krebszentrum-entwickelt-standardisierten-ansatz-zur-bewerutng-und-einfuehrung-von-biosimilars/?lang=de 2021-12-08T15:26:59+00:00 https://preview.ask-biosimilars.com/ressourcen/trastuzumab-biosimilar-und-kardiotoxizitaet-lilac-studie-zusammenfassung/?lang=de 2021-12-08T15:28:08+00:00 https://preview.ask-biosimilars.com/ressourcen/verstaendnis-von-biosimilars-im-gesundheitswesen-schluessel-zu-mehr-akzeptanz-zusammenfassung/?lang=de 2021-12-08T15:28:23+00:00 https://preview.ask-biosimilars.com/ressourcen/vergleich-der-aspekte-von-verfguebaren-lmwh-biosimilars-zusammenfasung/?lang=de 2021-12-08T15:28:29+00:00 https://preview.ask-biosimilars.com/ressourcen/how-best-to-illustrate-interchangeability-of-biosimilars-abstract/?lang=de 2021-12-08T15:29:10+00:00 https://preview.ask-biosimilars.com/ressourcen/isopp/?lang=de 2021-12-08T15:45:11+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/ISOPP_Logo_v2.png https://preview.ask-biosimilars.com/ressources/centre-de-cancer-developpe-approche-standardisee-pour-evaluer-et-mettre-en-oeuvre-biosimilaires/?lang=fr 2021-12-08T15:47:02+00:00 https://preview.ask-biosimilars.com/ressources/resume-biosimilaire-trastuzumab-et-toxicite-cardiaque-etude-lilac/?lang=fr 2021-12-08T15:47:07+00:00 https://preview.ask-biosimilars.com/ressources/resume-comprehension-des-biosimilaires-hcps-cle-conduite/?lang=fr 2021-12-08T15:47:24+00:00 https://preview.ask-biosimilars.com/ressources/resume-comparaison-des-aspects-des-biosimilaires-hbpm-disponibles/?lang=fr 2021-12-08T15:47:30+00:00 https://preview.ask-biosimilars.com/ressources/resume-comment-mieux-illustrer-l-interchangeabilite-des-biosimilaires/?lang=fr 2021-12-08T15:47:37+00:00 https://preview.ask-biosimilars.com/risorse/centro-oncologico-sviluppa-approccio-standardizzato-per-valutare-e-implementare-biosimilari/?lang=it 2021-12-08T16:18:46+00:00 https://preview.ask-biosimilars.com/risorse/abstract-trastuzumab-biosimilare-e-studio-di-tossicita-cardiaca/?lang=it 2021-12-08T16:18:52+00:00 https://preview.ask-biosimilars.com/risorse/abstract-comprensione-di-biosimilari-tra-operatori-sanitari-fondamentale-per-guidarne-ladozione/?lang=it 2021-12-08T16:19:10+00:00 https://preview.ask-biosimilars.com/risorse/stract-confronto-di-aspetti-di-biosimilari-lmwh-disponibili/?lang=it 2021-12-08T16:19:14+00:00 https://preview.ask-biosimilars.com/risorse/abstract-come-illustrare-al-meglio-lintercambiabilita-dei-biosimilari/?lang=it 2021-12-08T16:19:50+00:00 https://preview.ask-biosimilars.com/risorse/isopp/?lang=it 2021-12-08T16:20:02+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/ISOPP_Logo_v2.png https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E3%81%8C%E3%82%93-%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC-%E3%81%8C-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%AE-%E8%A9%95%E4%BE%A1-%E3%81%A8-%E5%B0%8E%E5%85%A5-%E3%81%AE/?lang=ja 2021-12-08T16:21:23+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E3%83%88%E3%83%A9%E3%83%B3%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%A8-%E6%96%B0%E6%AF%92%E6%80%A7-lilac-%E8%A9%A6/?lang=ja 2021-12-08T16:22:14+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E5%88%A9%E7%94%A8%E5%8F%AF%E8%83%BD%E3%81%AA-%E4%BD%8E%E5%88%86%E5%AD%90%E9%87%8F%E3%83%98%E3%83%91%E3%83%AA%E3%83%B3-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC/?lang=ja 2021-12-08T16:22:30+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E5%8C%BB%E7%99%82%E5%BE%93%E4%BA%8B%E8%80%85-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B-%E7%90%86%E8%A7%A3-%E3%81%8C-%E5%B0%8E/?lang=ja 2021-12-08T16:22:52+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%AE-%E4%BA%92%E6%8F%9B%E6%80%A7-%E3%82%92-%E3%81%A9%E3%81%AE%E3%82%88%E3%81%86%E3%81%AB-%E8%AA%AC%E6%98%8E-%E3%81%99%E3%82%8B/?lang=ja 2021-12-08T16:23:07+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/isopp/?lang=ja 2021-12-08T16:23:15+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/ISOPP_Logo_v2.png https://preview.ask-biosimilars.com/recursos/centro-integral-del-cancer-desarrolla-enfoque-estandarizado-para-evaluar-e-incorporar-biosimilares/?lang=es 2021-12-08T16:24:22+00:00 https://preview.ask-biosimilars.com/recursos/resumen-ensayo-lilac-biosimilar-trastuzumab-y-toxicidad-cardiaca/?lang=es 2021-12-08T16:24:27+00:00 https://preview.ask-biosimilars.com/recursos/resumen-comprension-de-biosimilares-entre-profesionales-sanitarios-es-esencial-para-impulsar-aceptacion/?lang=es 2021-12-08T16:24:47+00:00 https://preview.ask-biosimilars.com/recursos/resumen-comparacion-de-aspectos-de-biosimilares-hbpm-disponibles/?lang=es 2021-12-08T16:24:51+00:00 https://preview.ask-biosimilars.com/recursos/resumen-mejor-forma-de-ilustrar-la-intercambiabilidad-de-los-biosimilares/?lang=es 2021-12-08T16:24:57+00:00 https://preview.ask-biosimilars.com/resources/isopp/?lang=es 2021-12-08T16:25:20+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/ISOPP_Logo_v2.png https://preview.ask-biosimilars.com/resources/bopa/ 2022-01-14T11:54:42+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2022/01/bopa.png https://preview.ask-biosimilars.com/resources/latest-policy-review-and-effective-launch-of-biosimilars-abstract/ 2022-01-27T11:41:09+00:00 https://preview.ask-biosimilars.com/resources/improving-supportive-care-from-the-introduction-of-biosimilars-abstract/ 2022-01-27T13:34:43+00:00 https://preview.ask-biosimilars.com/resources/bioequivalence-in-first-population-pk-analysis-for-bevacizumab-biosimilar-abstract/ 2022-01-28T10:54:30+00:00 https://preview.ask-biosimilars.com/resources/biosimilars-set-to-become-integral-to-cancer-therapy/ 2022-01-28T14:36:26+00:00 https://preview.ask-biosimilars.com/resources/pegfilgrastim-biosimilar-in-preventing-chemotherapy-induced-neutropenia-in-patients-with-breast-cancer/ 2022-01-28T14:36:35+00:00 https://preview.ask-biosimilars.com/resources/myl-0140-is-bioequivalent-to-both-eu-and-us-trastuzumab/ 2022-01-28T14:36:44+00:00 https://preview.ask-biosimilars.com/resources/equivalence-study-to-compare-the-effects-of-abp-980-biosimilar-vs-reference-trastuzumab-in-breast-cancer/ 2022-01-28T14:37:29+00:00 https://preview.ask-biosimilars.com/resources/approval-of-trastuzumab-biosimilars-show-how-clinical-development-program-works-in-practice/ 2022-01-28T14:37:36+00:00 https://preview.ask-biosimilars.com/resources/maple-study-confirms-biosimilarity-between-abp-215-and-bevacizumab-rp-in-nsclc/ 2022-01-28T14:37:47+00:00 https://preview.ask-biosimilars.com/resources/bevacizumab-paves-the-way-for-extrapolation-of-indications/ 2022-01-28T14:37:56+00:00 https://preview.ask-biosimilars.com/resources/understanding-the-role-of-comparative-clinical-studies-in-biosimilars-evaluation-and-approval/ 2022-01-28T14:38:05+00:00 https://preview.ask-biosimilars.com/resources/trastuzumab-biosimilar-exerts-equivalent-orr-to-rp-in-women-with-erbb2-positive-metastatic-breast-cancer/ 2022-01-28T14:38:14+00:00 https://preview.ask-biosimilars.com/resources/comparative-pkpd-study-shows-biosimilarity-between-pegfilgrastim-biosimilar-and-originator/ 2022-01-28T14:38:22+00:00 https://preview.ask-biosimilars.com/resources/bevacizumab-biosimilar-for-metastatic-crc-iranian-phase-iii-study/ 2022-01-28T14:38:30+00:00 https://preview.ask-biosimilars.com/resources/trial-confirms-efficacy-and-safety-of-bcd-020-compared-to-reference-rituximab/ 2022-01-28T14:38:40+00:00 https://preview.ask-biosimilars.com/resources/acceptance-of-rituximab-biosimilar-use-during-24-months-post-approval/ 2022-01-28T14:38:56+00:00 https://preview.ask-biosimilars.com/resources/trastuzumab-biosimilars-have-potential-for-cost-savings-and-improved-utilisation/ 2022-01-28T14:42:12+00:00 https://preview.ask-biosimilars.com/resources/lower-cost-biosimilar-achieves-targets-in-cytotoxic-chemotherapy-anaemia/ 2022-01-28T14:42:18+00:00 https://preview.ask-biosimilars.com/resources/hcps-trust-in-biosimilars-key-to-ensuring-availability/ 2022-01-28T14:42:35+00:00 https://preview.ask-biosimilars.com/resources/trastuzumab-cuts-expensive-obstacle-to-breast-cancer-treatment/ 2022-01-28T14:42:44+00:00 https://preview.ask-biosimilars.com/recursos/estudio-de-equivalencia-para-comparar-los-efectos-del-biosimilar-abp-980-con-el-producto-de-referencia-trastuzumab-en-cancer-de-mama/?lang=es 2022-02-02T10:51:28+00:00 https://preview.ask-biosimilars.com/recursos/la-aprobacion-de-biosimilares-de-trastuzumab-muestra-como-funciona-en-la-practica-el-programa-de-desarrollo-clinico/?lang=es 2022-02-02T11:10:12+00:00 https://preview.ask-biosimilars.com/recursos/el-estudio-maple-confirma-la-biosimilitud-entre-abp-215-y-el-pr-bevacizumab-en-el-cpcnp/?lang=es 2022-02-02T11:21:21+00:00 https://preview.ask-biosimilars.com/recursos/bevacizumab-prepara-el-camino-para-la-extrapolacion-de-las-indicaciones/?lang=es 2022-02-02T11:27:48+00:00 https://preview.ask-biosimilars.com/recursos/entendiendo-el-papel-de-los-estudios-clinicos-comparativos-en-la-evaluacion-y-aprobacion-de-biosimilares/?lang=es 2022-02-02T11:35:02+00:00 https://preview.ask-biosimilars.com/recursos/biosimilar-de-trastuzumab-muestra-tro-equivalente-con-respecto-al-pr-en-mujeres-con-cancer-de-mama-metastasico-erbb2-positivo/?lang=es 2022-02-02T11:40:55+00:00 https://preview.ask-biosimilars.com/recursos/un-estudio-fcfd-comparativo-muestra-la-biosimilitud-entre-el-biosimilar-de-pegfilgrastim-y-el-producto-original/?lang=es 2022-02-02T11:47:02+00:00 https://preview.ask-biosimilars.com/recursos/estudio-en-fase-iii-irani-de-biosimilar-de-bevacizumab-para-ccr-metastasico/?lang=es 2022-02-02T11:51:59+00:00 https://preview.ask-biosimilars.com/recursos/un-ensayo-clinico-confirma-la-eficacia-y-la-seguridad-de-bcd-020-en-comparacion-con-el-producto-de-referencia-rituximab/?lang=es 2022-02-02T11:56:17+00:00 https://preview.ask-biosimilars.com/recursos/aceptacion-del-uso-del-biosimilar-de-rituximab-durante-los-24-meses-posteriores-a-su-aprobacion/?lang=es 2022-02-02T12:01:52+00:00 https://preview.ask-biosimilars.com/resources/efficacy-pharmacokinetics-and-safety-of-the-biosimilar-ct-p10/ 2022-02-02T12:17:40+00:00 https://preview.ask-biosimilars.com/recursos/eficacia-farmacocinetica-y-seguridad-del-biosimilar-ct-p10/?lang=es 2022-02-02T12:23:14+00:00 https://preview.ask-biosimilars.com/recursos/biosimilares-de-trastuzumab-ofrecen-la-posibilidad-de-ahorrar-gastos-y-mejorar-su-utilizacion/?lang=es 2022-02-02T12:48:55+00:00 https://preview.ask-biosimilars.com/resources/biosimilars-hold-the-potential-to-lower-costs-associated-with-stem-cell-transplant-in-oncology-and-haematology-related-care/ 2022-02-02T13:53:03+00:00 https://preview.ask-biosimilars.com/recursos/un-biosimilar-de-coste-mas-bajo-logra-los-objetivos-en-la-anemia-por-quimioterapia-citotoxica/?lang=es 2022-02-02T13:59:55+00:00 https://preview.ask-biosimilars.com/recursos/los-biosimilares-tienen-la-capacidad-de-reducir-los-costes-del-trasplante-de-celulas-madre/?lang=es 2022-02-02T14:21:18+00:00 https://preview.ask-biosimilars.com/resources/abp980-provides-additional-treatment-option-for-breast-and-gastric-cancer/ 2022-02-02T14:29:16+00:00 https://preview.ask-biosimilars.com/recursos/abp980-proporciona-una-opcion-de-tratamiento-adicional-para-el-cancer-de-mama-y-gastrico/?lang=es 2022-02-02T14:31:16+00:00 https://preview.ask-biosimilars.com/recursos/los-profesionales-sanitarios-confian-en-biosimilares-clave-para-garantizar-su-disponibilidad/?lang=es 2022-02-02T14:36:26+00:00 https://preview.ask-biosimilars.com/recursos/trastuzumab-elimina-un-obstaculo-caro-para-el-tratamiento-del-cancer-de-mama/?lang=es 2022-02-02T14:41:01+00:00 https://preview.ask-biosimilars.com/resources/current-and-future-roles-for-biosimilars-in-oncology/ 2022-02-02T15:29:40+00:00 https://preview.ask-biosimilars.com/recursos/funciones-actual-y-futura-de-los-biosimilares-en-oncologia/?lang=es 2022-02-02T15:34:39+00:00 https://preview.ask-biosimilars.com/recursos/los-biosimilares-llamados-a-convertirse-en-parte-integral-de-la-terapia-antineoplasica/?lang=es 2022-02-02T15:39:30+00:00 https://preview.ask-biosimilars.com/recursos/biosimilar-de-pegfilgrastim-para-prevenir-la-neutropenia-inducida-por-quimioterapia-en-pacientes-con-cancer-de-mama/?lang=es 2022-02-02T15:39:58+00:00 https://preview.ask-biosimilars.com/recursos/myl-0140-es-bioequivalente-a-trastuzumab-ue-y-ee-uu/?lang=es 2022-02-02T15:40:26+00:00 https://preview.ask-biosimilars.com/ressources/les-biosimilaires-deviendront-une-partie-integrante-du-traitement-du-cancer/?lang=fr 2022-02-03T08:08:56+00:00 https://preview.ask-biosimilars.com/resources/trends-in-biosimilar-development-seen-in-eu-may-improve-patient-access/ 2022-02-03T08:27:12+00:00 https://preview.ask-biosimilars.com/recursos/las-tendencias-en-el-desarrollo-de-biosimilares-surgidas-en-la-ue-pueden-mejorar-el-acceso-del-paciente/?lang=es 2022-02-03T08:27:12+00:00 https://preview.ask-biosimilars.com/ressources/les-tendances-de-developpement-de-biosimilaires-observees-dans-lue-pourraient-ameliorer-lacces-des-patients-a-un-traitement/?lang=fr 2022-02-03T08:27:29+00:00 https://preview.ask-biosimilars.com/ressources/resume-amelioration-des-soins-de-soutien-introduction-biosimilaires/?lang=fr 2022-02-03T09:25:33+00:00 https://preview.ask-biosimilars.com/ressources/le-biosimilaire-pegfilgrastim-dans-la-prevention-de-la-neutropenie-chimio-induite-chez-des-patientes-atteintes-de-cancer-du-sein/?lang=fr 2022-02-03T10:11:18+00:00 https://preview.ask-biosimilars.com/ressources/le-myl-0140-est-bioequivalent-a-la-fois-au-trastuzumab-europeen-et-americain/?lang=fr 2022-02-03T10:27:29+00:00 https://preview.ask-biosimilars.com/ressources/etude-dequivalence-pour-comparer-les-effets-du-biosimilaire-abp980-a-ceux-du-trastuzumab-de-reference-dans-le-cancer-du-sein/?lang=fr 2022-02-03T10:38:55+00:00 https://preview.ask-biosimilars.com/ressources/lhomologation-des-biosimilaires-du-trastuzumab-montre-comme-les-programmes-de-developpement-clinique-fonctionnent-en-pratique/?lang=fr 2022-02-03T10:44:47+00:00 https://preview.ask-biosimilars.com/ressources/letude-maple-confirme-la-biosimilarite-entre-labp215-et-le-produit-de-reference-le-bevacizumab-dans-le-nsclc/?lang=fr 2022-02-03T10:50:51+00:00 https://preview.ask-biosimilars.com/ressources/le-bevacizumab-ouvre-la-voie-a-lextrapolation-des-indications/?lang=fr 2022-02-03T11:02:19+00:00 https://preview.ask-biosimilars.com/ressources/comprehension-du-role-joue-par-les-etudes-cliniques-comparatives-dans-levaluation-et-lhomologation-des-biosimilaires/?lang=fr 2022-02-03T11:07:11+00:00 https://preview.ask-biosimilars.com/ressources/le-biosimilaire-du-trastuzumab-atteint-un-orr-equivalent-au-produit-de-reference-chez-les-femmes-atteintes-de-cancer-du-sein-metastatique-erbb2-positif/?lang=fr 2022-02-03T11:17:55+00:00 https://preview.ask-biosimilars.com/ressources/une-etude-comparative-pk/pd-montre-une-biosimilarite-entre-le-biosimilaire-pegfilgrastim-et-le-princeps/?lang=fr 2022-02-03T11:25:51+00:00 https://preview.ask-biosimilars.com/ressources/biosimilaire-du-bevacizumab-pour-le-ccr-metastatique-etude-iranienne-de-phase-iii/?lang=fr 2022-02-03T11:30:16+00:00 https://preview.ask-biosimilars.com/ressources/un-essai-confirme-lefficacite-et-linnocuite-du-bcd-020-par-rapport-au-rituximab-de-reference/?lang=fr 2022-02-03T11:36:46+00:00 https://preview.ask-biosimilars.com/ressources/acceptation-de-lutilisation-du-biosimilaire-du-rituximab-pendant-24mois-apres-lhomologation/?lang=fr 2022-02-03T11:42:33+00:00 https://preview.ask-biosimilars.com/ressources/efficacite-pharmacocinetique-et-innocuite-du-biosimilaire-ct-p10/?lang=fr 2022-02-03T11:48:46+00:00 https://preview.ask-biosimilars.com/ressources/les-biosimilaires-ont-le-potentiel-de-reduire-les-couts-de-greffe-de-cellules-souches/?lang=fr 2022-02-03T11:55:09+00:00 https://preview.ask-biosimilars.com/ressources/les-biosimilaires-du-trastuzumab-permettent-potentiellement-des-economies-de-couts-et-une-amelioration-de-lutilisation/?lang=fr 2022-02-03T12:01:19+00:00 https://preview.ask-biosimilars.com/ressources/moins-onereux-les-biosimilaires-atteignent-les-objectifs-fixes-dans-le-traitement-de-lanemie-chimio-induite-cytotoxique/?lang=fr 2022-02-03T12:10:40+00:00 https://preview.ask-biosimilars.com/ressources/role-actuel-et-futur-des-biosimilaires-en-oncologie/?lang=fr 2022-02-03T12:16:45+00:00 https://preview.ask-biosimilars.com/ressources/labp-980-offre-une-option-de-traitement-supplementaire-pour-le-cancer-du-sein-et-de-lestomac/?lang=fr 2022-02-03T12:21:51+00:00 https://preview.ask-biosimilars.com/ressources/la-confiance-des-professionnels-de-sante-dans-les-biosimilaires-est-fondamentale-pour-garantir-leur-disponibilite/?lang=fr 2022-02-03T12:26:59+00:00 https://preview.ask-biosimilars.com/ressources/le-trastuzumab-elimine-lobstacle-du-cout-dans-le-traitement-du-cancer-du-sein/?lang=fr 2022-02-03T12:31:28+00:00 https://preview.ask-biosimilars.com/risorse/la-tendenza-allo-sviluppo-dei-biosimilari-osservata-nellue-puo-migliorare-laccesso-dei-pazienti/?lang=it 2022-02-04T06:46:16+00:00 https://preview.ask-biosimilars.com/risorse/i-biosimilari-sono-destinati-a-diventare-parte-integrante-della-terapia-oncologica/?lang=it 2022-02-04T07:12:01+00:00 https://preview.ask-biosimilars.com/risorse/biosimilare-di-pegfilgrastim-per-la-prevenzione-della-neutropenia-indotta-da-chemioterapia-in-pazienti-affette-da-carcinoma-mammario/?lang=it 2022-02-04T07:17:58+00:00 https://preview.ask-biosimilars.com/risorse/myl-0140-e-bioequivalente-sia-di-ue-che-di-us-trastuzumab/?lang=it 2022-02-04T07:23:09+00:00 https://preview.ask-biosimilars.com/risorse/studio-di-equivalenza-per-confrontare-gli-effetti-del-biosimilare-abp-980-rispetto-al-trastuzumab-di-riferimento-nel-carcinoma-mammario/?lang=it 2022-02-04T07:29:19+00:00 https://preview.ask-biosimilars.com/risorse/lapprovazione-dei-biosimilari-di-trastuzumab-mostra-come-funziona-in-pratica-il-programma-di-sviluppo-clinico/?lang=it 2022-02-04T07:34:12+00:00 https://preview.ask-biosimilars.com/risorse/lo-studio-maple-conferma-la-biosimilarita-tra-abp-215-e-bevacizumab-rp-in-nsclc/?lang=it 2022-02-04T07:39:10+00:00 https://preview.ask-biosimilars.com/risorse/il-bevacizumab-apre-la-strada-allestrapolazione-delle-indicazioni/?lang=it 2022-02-04T07:43:42+00:00 https://preview.ask-biosimilars.com/risorse/comprendere-il-ruolo-degli-studi-clinici-comparativi-per-la-valutazione-e-lapprovazione-dei-biosimilari/?lang=it 2022-02-04T07:48:27+00:00 https://preview.ask-biosimilars.com/risorse/studio-pkpd-comparativo-dimostra-la-biosimilarita-tra-il-biosimilare-di-pegfilgrastim-e-il-relativo-originatore/?lang=it 2022-02-04T07:59:52+00:00 https://preview.ask-biosimilars.com/risorse/il-bevacizumab-biosimilare-per-il-crc-metastatico-studio-iraniano-di-fase-iii/?lang=it 2022-02-04T08:07:04+00:00 https://preview.ask-biosimilars.com/risorse/uno-studio-conferma-lefficacia-e-la-sicurezza-del-bcd-020-in-confronto-al-rituximab-di-riferimento/?lang=it 2022-02-04T08:14:56+00:00 https://preview.ask-biosimilars.com/risorse/accettazione-delluso-del-biosimilare-di-rituximab-nel-corso-di-24-mesi-dopo-lapprovazione/?lang=it 2022-02-04T08:28:03+00:00 https://preview.ask-biosimilars.com/risorse/efficacia-farmacocinetica-e-sicurezza-del-biosimilare-ct-p10/?lang=it 2022-02-04T08:33:58+00:00 https://preview.ask-biosimilars.com/risorse/i-biosimilari-possono-ridurre-i-costi-associati-al-trapianto-di-cellule-staminali/?lang=it 2022-02-04T08:40:22+00:00 https://preview.ask-biosimilars.com/risorse/i-costi-inferiori-dei-biosimilari-consentono-di-raggiungere-gli-obiettivi-per-lanemia-da-chemioterapia-citotossica/?lang=it 2022-02-04T09:18:03+00:00 https://preview.ask-biosimilars.com/risorse/ruoli-attuali-e-futuri-dei-biosimilari-in-oncologia/?lang=it 2022-02-04T09:23:15+00:00 https://preview.ask-biosimilars.com/risorse/abp980-fornisce-unulteriore-opzione-di-trattamento-del-carcinoma-mammario-e-gastrico/?lang=it 2022-02-04T09:26:28+00:00 https://preview.ask-biosimilars.com/risorse/la-fiducia-degli-hcp-nei-biosimilari-e-fondamentale-per-garantire-la-disponibilita/?lang=it 2022-02-04T09:31:45+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E5%8B%95%E5%90%91-%E3%81%A7-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E9%96%8B%E7%99%BA-%E8%A6%8B%E3%82%89%E3%82%8C%E3%82%8B-%E3%81%A7-eu-%E5%8F%AF%E8%83%BD%E6%80%A7%E3%81%8C%E3%81%82%E3%82%8B-%E6%94%B9%E5%96%84%E3%81%99%E3%82%8B-%E6%82%A3%E8%80%85-%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9/?lang=ja 2022-02-04T10:53:44+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%8C%E3%82%93-%E6%B2%BB%E7%99%82-%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6-%E4%B8%8D%E5%8F%AF%E6%AC%A0%E3%81%AA%E5%AD%98%E5%9C%A8-%E3%81%AB%E3%81%AA%E3%82%8B/?lang=ja 2022-02-04T10:57:55+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%9A%E3%82%B0%E3%83%95%E3%82%A3%E3%83%AB%E3%82%B0%E3%83%A9%E3%82%B9%E3%83%81%E3%83%A0-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B-%E4%BA%88%E9%98%B2-%E5%8C%96%E5%AD%A6%E7%99%82%E6%B3%95-%E8%AA%98%E7%99%BA%E6%80%A7-%E5%A5%BD%E4%B8%AD%E7%90%83%E6%B8%9B%E5%B0%91%E7%97%87-%E3%81%8A%E3%81%91%E3%82%8B-%E6%82%A3%E8%80%85-%E3%81%AE-%E4%B9%B3-%E3%81%8C%E3%82%93/?lang=ja 2022-02-04T11:02:34+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/myl-0140-%E3%81%A7%E3%81%82%E3%82%8B-%E7%94%9F%E7%89%A9%E5%AD%A6%E7%9A%84%E3%81%AB%E5%90%8C%E7%AD%89-%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6-%E3%81%A8-eu-%E3%81%8A%E3%82%88%E3%81%B3-us-%E3%83%88%E3%83%A9%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96/?lang=ja 2022-02-04T12:16:58+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E5%90%8C%E7%AD%89%E6%80%A7-%E8%A9%A6%E9%A8%93-%E3%81%A8-%E6%AF%94%E8%BC%83%E3%81%99%E3%82%8B-%E9%AB%98%E4%BE%A1-%E3%81%AE-abp-980-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%A8-%E5%8F%82%E7%85%A7-%E3%83%88%E3%83%A9%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96-%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B-%E4%B9%B3-%E3%81%8C%E3%82%93/?lang=ja 2022-02-04T12:23:12+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E6%89%BF%E8%AA%8D-%E3%81%AE-%E3%83%88%E3%83%A9%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E7%A4%BA%E3%81%99-%E3%81%A9%E3%81%AE%E3%82%88%E3%81%86%E3%81%AB-%E8%87%A8%E5%BA%8A-%E9%96%8B%E7%99%BA-%E3%83%97%E3%83%AD%E3%82%B0%E3%83%A9%E3%83%A0-%E6%A9%9F%E8%83%BD%E3%81%99%E3%82%8B-%E3%81%AB-%E5%AE%9F%E9%9A%9B/?lang=ja 2022-02-04T13:49:28+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/maple-%E8%A9%A6%E9%A8%93-%E7%A2%BA%E8%AA%8D-%E7%94%9F%E7%89%A9%E5%AD%A6%E7%9A%84%E9%A1%9E%E4%BC%BC%E6%80%A7-%E3%81%AE-abp-215-%E3%81%A8-%E3%83%99%E3%83%90%E3%82%B7%E3%82%BA%E3%83%9E%E3%83%96-%E5%8F%82%E7%85%A7%E8%A3%BD%E5%93%81-%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B-nsclc/?lang=ja 2022-02-04T13:53:39+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%99%E3%83%90%E3%82%B7%E3%82%BA%E3%83%9E%E3%83%96-%E9%96%8B%E3%81%8F-%E9%81%93-%E3%81%AB-%E5%A4%96%E6%8C%BF-%E3%81%AE-%E9%81%A9%E5%BF%9C%E7%97%87/?lang=ja 2022-02-04T14:07:25+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E7%90%86%E8%A7%A3%E3%81%99%E3%82%8B-%E5%BD%B9%E5%89%B2-%E3%81%AE-%E6%AF%94%E8%BC%83-%E8%87%A8%E5%BA%8A-%E8%A9%A6%E9%A8%93-%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E8%A9%95%E4%BE%A1-%E3%81%A8-%E6%89%BF%E8%AA%8D/?lang=ja 2022-02-04T14:11:28+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%88%E3%83%A9%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E7%99%BA%E6%8F%AE%E3%81%99%E3%82%8B-%E5%90%8C%E7%AD%89-orr-%E3%81%A8-rp-%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6-%E6%82%A3%E8%80%85-%E3%81%AE-erbb2-%E9%99%BD%E6%80%A7-%E8%BB%A2%E7%A7%BB%E6%80%A7-%E4%B9%B3-%E3%81%8C%E3%82%93/?lang=ja 2022-02-07T07:25:10+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E6%AF%94%E8%BC%83-pkpd-%E8%A9%A6%E9%A8%93-%E7%A2%BA%E8%AA%8D-%E7%94%9F%E7%89%A9%E5%AD%A6%E7%9A%84%E9%A1%9E%E4%BC%BC%E6%80%A7-%E3%81%A8-%E3%83%9A%E3%82%B0%E3%83%95%E3%82%A3%E3%83%AB%E3%82%B0%E3%83%A9%E3%82%B9%E3%83%81%E3%83%A0-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%A8-%E3%82%AA%E3%83%AA%E3%82%B8%E3%83%8D%E3%83%BC%E3%82%BF%E3%83%BC/?lang=ja 2022-02-07T07:29:08+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%99%E3%83%90%E3%82%B7%E3%82%BA%E3%83%9E%E3%83%96-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E7%94%A8-%E8%BB%A2%E7%A7%BB%E6%80%A7-%E5%A4%A7%E8%85%B8%E3%81%8C%E3%82%93-%E3%82%A4%E3%83%A9%E3%83%B3%E3%81%AE-%E7%9B%B8-iii-%E8%A9%A6%E9%A8%93/?lang=ja 2022-02-07T07:35:22+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E8%A9%A6%E9%A8%93-%E7%A2%BA%E8%AA%8D-%E6%9C%89%E5%8A%B9%E6%80%A7-%E3%81%A8-%E5%AE%89%E5%85%A8%E6%80%A7-%E3%81%AE-bcd-020-%E6%AF%94%E8%BC%83%E3%81%97%E3%81%9F-%E3%81%A8-%E5%8F%82%E7%85%A7-%E3%83%AA%E3%83%84%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96/?lang=ja 2022-02-07T07:39:03+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E5%8F%97%E5%AE%B9%E6%80%A7-%E3%81%AE-%E3%83%AA%E3%83%84%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E4%BD%BF%E7%94%A8-%E9%96%93-24-%E3%82%B1%E6%9C%88-%E5%BE%8C-%E6%89%BF%E8%AA%8D/?lang=ja 2022-02-07T07:42:50+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E6%9C%89%E5%8A%B9%E6%80%A7-%E8%96%AC%E7%89%A9%E5%8B%95%E6%85%8B-%E3%81%8A%E3%82%88%E3%81%B3-%E5%AE%89%E5%85%A8%E6%80%A7-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-ct-p10/?lang=ja 2022-02-07T07:51:46+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%82%E3%82%8B-%E5%8F%AF%E8%83%BD%E6%80%A7-%E3%81%99%E3%82%8B-%E4%BD%8E%E6%B8%9B-%E5%B9%B9-%E7%B4%B0%E8%83%9E-%E7%A7%BB%E6%A4%8D-%E3%82%B3%E3%82%B9%E3%83%88/?lang=ja 2022-02-07T07:58:08+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E7%8F%BE%E5%9C%A8-%E3%81%A8-%E5%B0%86%E6%9D%A5-%E5%BD%B9%E5%89%B2-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%A7%E3%81%AE-%E3%81%8C%E3%82%93%E9%A0%98%E5%9F%9F/?lang=ja 2022-02-07T08:15:44+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/abp980-%E6%8F%90%E4%BE%9B%E3%81%99%E3%82%8B-%E6%96%B0%E3%81%9F%E3%81%AA-%E6%B2%BB%E7%99%82-%E9%81%B8%E6%8A%9E%E8%82%A2-%E3%81%AB-%E4%B9%B3-%E3%82%84-%E8%83%83-%E3%81%8C%E3%82%93/?lang=ja 2022-02-07T08:19:23+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E5%8C%BB%E7%99%82%E5%BE%93%E4%BA%8B%E8%80%85-%E4%BF%A1%E9%A0%BC-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%83%9D%E3%82%A4%E3%83%B3%E3%83%88-%E3%81%AE-%E7%A2%BA%E4%BF%9D-%E5%8F%AF%E7%94%A8%E6%80%A7/?lang=ja 2022-02-07T08:24:27+00:00 https://preview.ask-biosimilars.com/recursos/resumen-examen-politicas-comercializacion-efectiva-de-biosimilares/?lang=es 2022-02-14T09:03:21+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E3%83%99%E3%83%90%E3%82%B7%E3%82%BA%E3%83%9E%E3%83%96-%E3%81%AE-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%8C-%E5%88%9D%E3%81%AE-%E9%9B%86%E5%9B%A3-pk-%E8%A7%A3%E6%9E%90/?lang=ja 2022-02-14T09:07:19+00:00 https://preview.ask-biosimilars.com/ressources/resume-bioequivalence-confirmee-premiere-population-analyse-pk-biosimilaire-bevacizumab/?lang=fr 2022-02-14T09:07:40+00:00 https://preview.ask-biosimilars.com/ressourcen/bioaequivalenz-in-erster-population-pk-analyse-fuer-ein-bevacizumab-biosimilar-bestaetigt-zusammenfassung/?lang=de 2022-02-14T09:07:53+00:00 https://preview.ask-biosimilars.com/risorse/abstract-bioequivalenza-confermata-nella-prima-analisi-popolazione-pk-per-un-bevacizumab-biosimilare/?lang=it 2022-02-14T09:08:05+00:00 https://preview.ask-biosimilars.com/recursos/resumen-confirmacion-bioequivalencia-en-el-primer-analisis-farmacocinetico-de-poblacion-de-un-biosimilar-de-bevacizumab/?lang=es 2022-02-14T09:08:20+00:00 https://preview.ask-biosimilars.com/ressourcen/verbesserung-der-unterstuetzenden-behandlung-durch-biosimilars-zusammenfassung/?lang=de 2022-02-14T09:08:33+00:00 https://preview.ask-biosimilars.com/risorse/abstract-migliorare-terapie-sostegno-dallintroduzione-di-biosimilari/?lang=it 2022-02-14T09:08:47+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%AE-%E5%B0%8E%E5%85%A5-%E3%81%8B%E3%82%89%E3%81%AE-%E6%94%AF%E6%8C%81%E7%99%82%E6%B3%95-%E3%81%AE-%E6%94%B9%E5%96%84-%E8%A6%81/?lang=ja 2022-02-14T09:08:58+00:00 https://preview.ask-biosimilars.com/recursos/resumen-mejora-cuidados-de-apoyo-mediante-introduccion-de-biosimilares/?lang=es 2022-02-14T09:09:11+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E6%9C%80%E6%96%B0%E3%81%AE-%E3%83%9D%E3%83%AA%E3%82%B7%E3%83%BC-%E3%83%AC%E3%83%93%E3%83%A5%E3%83%BC-%E3%81%A8-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%AE-%E5%8A%B9/?lang=ja 2022-02-14T09:16:28+00:00 https://preview.ask-biosimilars.com/risorse/abstract-ultimo-riesame-politico-e-lancio-efficace-dei-biosimilari/?lang=it 2022-02-14T09:16:42+00:00 https://preview.ask-biosimilars.com/ressourcen/latest-policy-review-and-effective-launch-of-biosimilars-abstract/?lang=de 2022-02-14T09:16:56+00:00 https://preview.ask-biosimilars.com/ressources/resume-dernier-examen-des-politiques-et-lancement-efficace-de-biosimilaires/?lang=fr 2022-02-14T09:17:10+00:00 https://preview.ask-biosimilars.com/risorse/trastuzumab-supera-lostacolo-dei-costi-per-il-trattamento-del-carcinoma-mammario/?lang=it 2022-02-16T10:40:11+00:00 https://preview.ask-biosimilars.com/risorse/i-biosimilari-di-trastuzumab-inducono-potenzialmente-un-risparmio-sui-costi-e-un-migliore-utilizzo/?lang=it 2022-02-16T10:43:28+00:00 https://preview.ask-biosimilars.com/risorse/il-biosimilare-di-trastuzumab-mostra-un-tasso-di-risposta-globale-equivalente-al-farmaco-di-riferimento-in-donne-affette-da-carcinoma-mammario-metastatico-erbb2-positivo/?lang=it 2022-02-16T10:45:55+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%88%E3%83%A9%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96-%E8%BB%BD%E6%B8%9B%E3%81%99%E3%82%8B-%E9%AB%98%E4%BE%A1%E3%81%AA-%E9%9A%9C%E5%A3%81-%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B-%E4%B9%B3-%E3%81%8C%E3%82%93-%E6%B2%BB%E7%99%82/?lang=ja 2022-02-16T10:48:37+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%82%88%E3%82%8A%E5%AE%89%E4%BE%A1-%E4%BE%A1%E6%A0%BC-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E9%81%94%E6%88%90-%E7%9B%AE%E6%A8%99-%E3%81%A7-%E6%8A%97%E3%81%8C%E3%82%93%E5%89%A4-%E5%8C%96%E5%AD%A6%E7%99%82%E6%B3%95-%E8%B2%A7%E8%A1%80/?lang=ja 2022-02-16T10:51:48+00:00 https://preview.ask-biosimilars.com/%E3%83%AA%E3%82%BD%E3%83%BC%E3%82%B9/%E3%83%88%E3%83%A9%E3%82%B9%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96-%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B7%E3%83%9F%E3%83%A9%E3%83%BC-%E3%81%82%E3%82%8B-%E5%8F%AF%E8%83%BD%E6%80%A7-%E3%81%AE-%E7%B5%8C%E8%B2%BB-%E5%89%8A%E6%B8%9B-%E3%81%A8-%E5%A2%97%E5%8A%A0-%E5%88%A9%E7%94%A8/?lang=ja 2022-02-16T10:55:00+00:00 https://preview.ask-biosimilars.com/ressourcen/trends-in-biosimilar-development-seen-in-eu-may-improve-patient-access/?lang=de 2022-03-14T10:38:42+00:00 https://preview.ask-biosimilars.com/ressourcen/biosimilars-werden-zum-wesentlichen-teil-der-krebstherapie/?lang=de 2022-03-14T10:44:22+00:00 https://preview.ask-biosimilars.com/ressourcen/pegfilgrastim-biosimilar-zur-vorbeugung-von-chemotherapie-induzierter-neutropenie-bei-patientinnen-mit-brustkrebs/?lang=de 2022-03-14T10:49:28+00:00 https://preview.ask-biosimilars.com/ressourcen/myl-0140-ist-bioaquivalent-zu-eu-und-us-trastuzumab/?lang=de 2022-03-14T10:56:01+00:00 https://preview.ask-biosimilars.com/ressourcen/aquivalenzstudie-zum-vergleich-der-wirkungen-von-abp-980-biosimilar-versus-referenz-trastuzumab-bei-brustkrebs/?lang=de 2022-03-14T11:00:31+00:00 https://preview.ask-biosimilars.com/ressourcen/zulassung-von-trastuzumab-biosimilars-zeigen-wie-klinische-entwicklungsprogramme-in-der-praxis-vorgehen/?lang=de 2022-03-14T11:06:14+00:00 https://preview.ask-biosimilars.com/ressourcen/maple-studie-bestatigt-biosimilaritat-zwischen-abp-215-und-bevacizumab-rp-bei-nsclc/?lang=de 2022-03-14T11:13:02+00:00 https://preview.ask-biosimilars.com/ressourcen/bevacizumab-pflastert-den-weg-fur-extrapolation-der-indikationen/?lang=de 2022-03-14T11:17:46+00:00 https://preview.ask-biosimilars.com/ressourcen/rolle-vergleichender-klinischer-studien-bei-bewertung-und-zulassung-von-biosimilars/?lang=de 2022-03-14T11:24:08+00:00 https://preview.ask-biosimilars.com/ressourcen/trastuzumab-biosimilar-erzielt-aquivalente-orr-zu-rp-bei-frauen-mit-erbb2-positivem-metastasiertem-brustkrebs/?lang=de 2022-03-14T11:37:57+00:00 https://preview.ask-biosimilars.com/ressourcen/vergleichende-pkpd-studie-zeigt-bioahnlichkeit-zwischen-pegfilgrastim-biosimilar-und-ursprungs-biologika/?lang=de 2022-03-14T11:45:00+00:00 https://preview.ask-biosimilars.com/ressourcen/bevacizumab-biosimilar-fur-metastasierendes-crc-iranische-phase-iii-studie/?lang=de 2022-03-14T11:49:30+00:00 https://preview.ask-biosimilars.com/ressourcen/studie-bestatigt-wirksamkeit-und-sicherheit-von-bcd-020-im-vergleich-zu-referenz-rituximab/?lang=de 2022-03-14T11:54:57+00:00 https://preview.ask-biosimilars.com/ressourcen/akzeptanz-von-rituximab-biosimilar-verwendung-24-monaten-nach-zulassung/?lang=de 2022-03-14T12:00:20+00:00 https://preview.ask-biosimilars.com/resources/wirksamkeit-pharmakokinetik-und-sicherheit-des-biosimilars-ct-p10/?lang=de 2022-03-14T12:07:19+00:00 https://preview.ask-biosimilars.com/ressourcen/biosimilars-haben-potenzial-zur-senkung-der-kosten-von-stammzellen-transplantaten/?lang=de 2022-03-14T12:12:45+00:00 https://preview.ask-biosimilars.com/ressourcen/trastuzumab-biosimilars-haben-potenzial-fur-kosteneinsparungen-und-bessere-nutzung/?lang=de 2022-03-14T12:17:02+00:00 https://preview.ask-biosimilars.com/ressourcen/kostengunstigeres-biosimilar-erreicht-ziele-bei-zytotoxischer-chemotherapie-anamie/?lang=de 2022-03-14T12:21:51+00:00 https://preview.ask-biosimilars.com/ressourcen/aktuelle-und-kunftige-anwendungen-von-biosimilars-in-der-onkologie/?lang=de 2022-03-14T12:25:12+00:00 https://preview.ask-biosimilars.com/ressourcen/abp980-bietet-eine-zusatzliche-behandlungsoption-fur-brust-und-magenkrebs/?lang=de 2022-03-14T12:29:33+00:00 https://preview.ask-biosimilars.com/ressourcen/hcps-vertrauen-in-biosimilars-schlussel-zur-sicherstellung-der-verfugbarkeit/?lang=de 2022-03-14T12:34:17+00:00 https://preview.ask-biosimilars.com/ressourcen/trastuzumab-senkt-teures-hindernis-fur-brustkrebs-behandlung/?lang=de 2022-03-14T12:38:19+00:00 https://preview.ask-biosimilars.com/%E8%B3%87%E5%8A%9B/%E6%97%A5%E6%9C%AC-%E5%9B%BD%E5%AE%B6-%E8%A6%8F%E5%88%B6-%E5%BD%93%E5%B1%80-%E3%82%AC%E3%82%A4%E3%83%80%E3%83%B3%E3%82%B9-%E8%A6%81%E7%B4%84-%E6%96%87%E6%9B%B8/?lang=ja 2022-03-16T12:47:41+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Japan.png https://preview.ask-biosimilars.com/resources/national-guideline-lorem-ipsum/ 2022-03-16T13:47:50+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_the_United_Kingdom.png https://preview.ask-biosimilars.com/resources/canadian-national-regulatory-agency-guidance-summary-document/ 2022-03-16T13:48:01+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Canada_Pantone.png https://preview.ask-biosimilars.com/resources/japanese-national-regulatory-agency-guidance-summary-document/ 2022-03-16T13:48:13+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Japan.png https://preview.ask-biosimilars.com/ressources/reglementation-relative-aux-biosimilaires-dans-lunion-europeenne?lang=fr 2022-03-17T10:57:38+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/ressourcen/regulierung-fur-biosimilars-in-der-europaischen-union?lang=de 2022-03-17T10:58:14+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/ressources/isopp/?lang=fr 2022-03-24T13:18:01+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/ISOPP_Logo_v2.png https://preview.ask-biosimilars.com/resources/isopp/ 2022-03-24T13:48:36+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/ISOPP_Logo_v2.png https://preview.ask-biosimilars.com/recursos/regulacion-sobre-biosimilares-en-la-union-europea?lang=es 2022-03-24T14:26:01+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/reglementation-relative-aux-biosimilaires-dans-lunion-europeenne/?lang=fr 2022-03-24T14:48:47+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/risorse/normativa-sui-biosimilari-nellunione-europea/?lang=it 2022-03-24T15:14:51+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/recursos/regulacion-sobre-biosimilares-en-la-union-europea/?lang=es 2022-03-24T15:26:10+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/ressourcen/zusammenfassung-2-der-leitlinien-der-nationalen-regulierungsbehoerden-der-eu/?lang=de 2022-03-24T15:31:04+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png https://preview.ask-biosimilars.com/resources/eu-national-regulatory-agency-guidance-summary-document-2/ 2022-10-20T09:47:52+00:00 https://preview.ask-biosimilars.com/wp-content/uploads/2021/07/Flag_of_Europe.png